Opus Genetics, Inc. Net Cash Provided by (Used in) Operating Activities, Continuing Operations
Opus Genetics, Inc. (IRD) reported Net Cash Provided by (Used in) Operating Activities, Continuing Operations of -$15.42 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations · last filed 2018-03-09
- Opus Genetics, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-12-31 was -$3.70M.
- Opus Genetics, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-09-30 was -$3.45M.
- Opus Genetics, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-06-30 was -$4.10M.
- Opus Genetics, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2017-03-31 was -$4.17M.
- Opus Genetics, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2017 was -$15.42M.
- Opus Genetics, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2016 was -$13.23M.
- Opus Genetics, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2015 was -$17.35M.
- Opus Genetics, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2014 was -$11.04M.
| Period end | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 132 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 135 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 138 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 141 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 144 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 147 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 150 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 153 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 156 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2017-12-31 | -$3.70M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | -$7.15M derived: sum of 2 quarters · filed 2018-03-09 | -$11.25M derived: sum of 3 quarters · filed 2018-03-09 | -$15.42M 10-K · filed 2018-03-09 | |||||||||
| 2017-09-30 | -$3.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | -$7.55M derived: sum of 2 quarters · filed 2017-11-03 | -$11.72M 10-Q · filed 2017-11-03 | -$13.21M derived: sum of 4 quarters · filed 2018-03-09 | |||||||||
| 2017-06-30 | -$4.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | -$8.27M 10-Q · filed 2017-08-04 | -$9.76M derived: sum of 3 quarters · filed 2018-03-09 | -$12.88M derived: sum of 4 quarters · filed 2018-03-09 | |||||||||
| 2017-03-31 | -$4.17M 10-Q · filed 2017-05-03 | -$5.66M derived: sum of 2 quarters · filed 2018-03-09 | -$8.78M derived: sum of 3 quarters · filed 2018-03-09 | -$13.85M derived: sum of 4 quarters · filed 2018-03-09 | |||||||||
| 2016-12-31 | -$1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | -$4.61M derived: sum of 2 quarters · filed 2018-03-09 | -$9.68M derived: sum of 3 quarters · filed 2018-03-09 | -$13.23M 10-K · filed 2018-03-09 | |||||||||
| 2016-09-30 | -$3.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | -$8.18M derived: sum of 2 quarters · filed 2017-11-03 | -$11.73M 10-Q · filed 2017-11-03 | -$16.14M derived: sum of 4 quarters · filed 2018-03-09 | |||||||||
| 2016-06-30 | -$5.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | -$8.61M 10-Q · filed 2017-08-04 | -$13.02M derived: sum of 3 quarters · filed 2018-03-09 | -$17.52M derived: sum of 4 quarters · filed 2018-03-09 | |||||||||
| 2016-03-31 | -$3.55M 10-Q · filed 2017-05-03 | -$7.96M derived: sum of 2 quarters · filed 2018-03-09 | -$12.46M derived: sum of 3 quarters · filed 2018-03-09 | -$16.86M derived: sum of 4 quarters · filed 2018-03-09 | |||||||||
| 2015-12-31 | -$4.41M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | -$8.91M derived: sum of 2 quarters · filed 2018-03-09 | -$13.31M derived: sum of 3 quarters · filed 2018-03-09 | -$17.35M 10-K · filed 2018-03-09 | |||||||||
| 2015-09-30 | -$4.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | -$8.91M derived: sum of 2 quarters · filed 2016-11-04 | -$12.94M 10-Q · filed 2016-11-04 | -$15.86M derived: sum of 4 quarters · filed 2017-02-24 | |||||||||
| 2015-06-30 | -$4.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | -$8.44M 10-Q · filed 2016-08-05 | -$11.35M derived: sum of 3 quarters · filed 2017-02-24 | -$13.96M derived: sum of 4 quarters · filed 2017-02-24 | |||||||||
| 2015-03-31 | -$4.04M 10-Q · filed 2016-05-06 | -$6.95M derived: sum of 2 quarters · filed 2017-02-24 | -$9.55M derived: sum of 3 quarters · filed 2017-02-24 | -$12.50M derived: sum of 4 quarters · filed 2017-02-24 | |||||||||
| 2014-12-31 | -$2.91M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-24 | -$5.51M derived: sum of 2 quarters · filed 2017-02-24 | -$8.46M derived: sum of 3 quarters · filed 2017-02-24 | -$11.04M 10-K · filed 2017-02-24 | |||||||||
| 2014-09-30 | -$2.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-02 | -$5.55M derived: sum of 2 quarters · filed 2015-11-02 | -$8.13M 10-Q · filed 2015-11-02 | -$10.38M derived: sum of 4 quarters · filed 2016-03-14 | |||||||||
| 2014-06-30 | -$2.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | -$5.53M 10-Q · filed 2015-08-07 | -$7.78M derived: sum of 3 quarters · filed 2016-03-14 | -$9.46M derived: sum of 4 quarters · filed 2016-03-14 | |||||||||
| 2014-03-31 | -$2.58M 10-Q · filed 2015-05-08 | -$4.83M derived: sum of 2 quarters · filed 2016-03-14 | -$6.51M derived: sum of 3 quarters · filed 2016-03-14 | -$9.01M derived: sum of 4 quarters · filed 2016-03-14 | -$69.18M 10-Q · filed 2014-05-14 | ||||||||
| 2013-12-31 | -$2.25M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | -$3.93M derived: sum of 2 quarters · filed 2016-03-14 | -$6.43M derived: sum of 3 quarters · filed 2016-03-14 | -$7.98M 10-K · filed 2016-03-14 | -$66.61M 10-K · filed 2014-03-21 | ||||||||
| 2013-09-30 | -$1.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | -$4.18M derived: sum of 2 quarters · filed 2014-11-12 | -$5.74M 10-Q · filed 2014-11-12 | -$6.81M derived: sum of 4 quarters · filed 2014-11-12 | -$64.36M 10-Q · filed 2013-11-13 | ||||||||
| 2013-06-30 | -$2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-13 | -$4.06M 10-Q · filed 2014-08-13 | -$5.13M derived: sum of 3 quarters · filed 2014-08-13 | -$6.78M derived: sum of 4 quarters · filed 2014-08-13 | -$62.68M 10-Q · filed 2013-08-12 | ||||||||
| 2013-03-31 | -$1.55M 10-Q · filed 2014-05-14 | -$2.63M derived: sum of 2 quarters · filed 2014-05-14 | -$4.27M derived: sum of 3 quarters · filed 2014-05-14 | -$6.25M derived: sum of 4 quarters · filed 2014-05-14 | -$60.17M 10-Q · filed 2013-05-09 | ||||||||
| 2012-12-31 | -$1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-21 | -$2.72M derived: sum of 2 quarters · filed 2014-03-21 | -$4.70M derived: sum of 3 quarters · filed 2014-03-21 | -$6.62M 10-K · filed 2014-03-21 | -$58.62M 10-K · filed 2013-03-22 | ||||||||
| 2012-09-30 | -$1.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-13 | -$3.63M derived: sum of 2 quarters · filed 2013-11-13 | -$5.55M 10-Q · filed 2013-11-13 | -$10.42M derived: sum of 4 quarters · filed 2013-11-13 | -$57.55M 10-Q · filed 2012-11-08 | ||||||||
| 2012-06-30 | -$1.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-12 | -$3.90M 10-Q · filed 2013-08-12 | -$8.78M derived: sum of 3 quarters · filed 2013-08-12 | -$11.94M derived: sum of 4 quarters · filed 2013-08-12 | -$55.90M 10-Q · filed 2012-08-08 | ||||||||
| 2012-03-31 | -$1.92M 10-Q · filed 2013-05-09 | -$6.80M derived: sum of 2 quarters · filed 2013-05-09 | -$9.96M derived: sum of 3 quarters · filed 2013-05-09 | -$15.02M derived: sum of 4 quarters · filed 2013-05-09 | -$53.92M 10-Q · filed 2012-05-09 | ||||||||
| 2011-12-31 | -$4.88M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-22 | -$8.04M derived: sum of 2 quarters · filed 2013-03-22 | -$13.10M derived: sum of 3 quarters · filed 2013-03-22 | -$15.53M 10-K · filed 2013-03-22 | |||||||||
| 2011-09-30 | -$3.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | -$8.23M derived: sum of 2 quarters · filed 2012-11-08 | -$10.65M 10-Q · filed 2012-11-08 | -$13.07M derived: sum of 4 quarters · filed 2012-11-08 | |||||||||
| 2011-06-30 | -$5.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-08 | -$7.49M 10-Q · filed 2012-08-08 | -$9.91M derived: sum of 3 quarters · filed 2012-08-08 | -$11.50M derived: sum of 4 quarters · filed 2012-08-08 | |||||||||
| 2011-03-31 | -$2.43M 10-Q · filed 2012-05-09 | -$4.85M derived: sum of 2 quarters · filed 2012-05-09 | -$6.43M derived: sum of 3 quarters · filed 2012-05-09 | ||||||||||
| 2010-12-31 | -$2.42M derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-16 | -$4.01M derived: sum of 2 quarters · filed 2012-03-16 | -$6.99M 10-K · filed 2012-03-16 | ||||||||||
| 2010-09-30 | -$1.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-09 | -$4.57M 10-Q · filed 2011-11-09 | |||||||||||
| 2010-06-30 | -$2.98M 10-Q · filed 2011-08-09 | ||||||||||||
| 2009-12-31 | -$5.15M 10-K · filed 2012-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |